Immune responses to myelin proteins in Guillain-Barre syndrome
- 10 October 2007
- journal article
- research article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 79 (6), 664-671
- https://doi.org/10.1136/jnnp.2007.123943
Abstract
Background: Potential target autoantigens in the demyelinating form of Guillain–Barré syndrome (GBS) include the myelin proteins PMP22, P0 and P2. Methods: We investigated immunoreactivity to P0, P2 and PMP22 proteins in 37 patients with GBS and 32 healthy controls. Results: Antibodies to PMP22 or P0 peptides were detected at presentation in only 5 out of 37 patients. In ELISPOT assays, blood mononuclear cells from 15 out of 24 patients with GBS, but none of the control subjects, produced interleukin-10 (IL-10) in response to peptides from proteins P0, P2 or PMP22 (p = 0.0003). The cells from only two patients produced interferon-γ (IFNγ). The cells from 11 patients with GBS had increased IL-10 responses to peptides representing sequences from the extracellular domains of PMP22 before intravenous immunoglobulin (IVIg) treatment (p = 0.006). The cells from 11 patients with GBS, including 7 who responded to the extracellular domains of PMP22, had increased IL-10 responses to the intracellular domain of P0 before (p = 0.005) and those from 9 patients after they had been treated with IVIg (p = 0.01). Conclusions: Antibodies to P0 and PMP22 protein peptides do occur in GBS but are uncommon. Circulating mononuclear cell IFNγ responses to P0, P2 and PMP22 myelin protein peptides are rare, but IL-10 responses occur significantly more often than in normal subjects. They might be part of a harmful pathogenetic process or represent a regulatory response.This publication has 29 references indexed in Scilit:
- Antibody responses to peptides of peripheral nerve myelin proteins P0 and P2 in patients with inflammatory demyelinating neuropathyJournal of Neurology, Neurosurgery & Psychiatry, 2006
- T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathyJournal of Neurology, Neurosurgery & Psychiatry, 2005
- Antibodies to peripheral nerve myelin proteins in chronic inflammatory demyelinating polyradiculoneuropathyJournal of the Peripheral Nervous System, 2005
- Advances in understanding and treatment of immune‐mediated disorders of the peripheral nervous systemMuscle & Nerve, 2004
- The dual role of IL-10Trends in Immunology, 2003
- Interleukin-10 and the Interleukin-10 ReceptorAnnual Review of Immunology, 2001
- Electrophysiological classification of guillain‐barré syndrome: Clinical associations and outcomeAnnals of Neurology, 1998
- Anti‐ganglioside GM1 antibodies in guillain‐barré syndrome and their relationship to Campylobacter jejuni infectionAnnals of Neurology, 1995
- Cell adhesion molecules of the immunoglobulin supergene family as tissue‐specific autoantigens: induction of experimental allergic neuritis (EAN) by PO protein‐specific T cell linesEuropean Journal of Immunology, 1992
- New minimum length requirement for a T cell epitope for experimental allergic neuritisJournal of Neuroimmunology, 1990